Patent ID: 7179792

Claim:
A method for effecting the or treatment of a lipid metabolism disorder or metabolic syndrome in a patient comprising administering a pharmaceutically effective amount of a composition of matter comprising a compound of formula I in which R 1 is methyl, ethyl, propyl, or butyl; R 2 is H, —OH, —NH 2 , or —NH—(C 1 –C 6 )-alkyl; R 3 is a saccharide residue, disaccharide residue, trisaccharide residue, or tetrasaccharide residue, wherein the saccharide residue, disaccharide residue, trisaccharide residue or tetrasaccharide residue is optionally substituted one or more times by a saccharide protective group; or amino acid residue, diamino acid residue, triamino acid residue, or tetraamino acid residue, wherein the amino acid residue, diamino acid residue, triamino acid residue or tetraamino acid residue is optionally substituted one or more times by an amino acid protective group; R 4 is methyl, ethyl, propyl, or butyl; R 5 is methyl, ethyl, propyl, or butyl; Z is —(C═O) n —C 0 –C 16 -alkyl-, —(C═O) n —C 0 –C 16 -alkyl-NH—, —(C═O) n —C 0 –C 16 -alkyl-O—, —(C═O) n —C 1 –C 16 -alkyl-(C═O) m —, or a covalent bond; n is 0 or 1; and m is 0 or 1; or a pharmaceutically acceptable salt thereof, with at least one other active ingredient, or a pharmaceutically acceptable salt thereof, wherein the other active ingredient is selected from the group consisting of ezetimibe and carob pulp to the patient.